Partial
Needs Review
Patient Risk:
Moderate
Summary
The response includes several label-consistent insomnia and dosing-timing statements, but it also makes multiple unsupported/overstated safety claims (notably alcohol/opioid/sedative risks and specific serious symptom triggers) and omits key label dosing limits and individualized/elderly dosing details.
Category Scores
Accurate Statements
Zaleplon is used to treat insomnia.
Label excerpt: “Sonata is indicated for the short-term treatment of insomnia.”
Zaleplon is used to help people fall asleep.
Label excerpt: “has been shown to decrease the time to sleep onset…”
Zaleplon is intended for sleep induction and dosing timing matters.
Label excerpt: “Sonata… has CNS-depressant effects… should only be ingested immediately prior to going to bed or after… difficulty falling asleep.” and “Timing of Drug Administration…”
Zaleplon is typically taken when a person has trouble getting to sleep.
Label excerpt: “should be taken immediately before bedtime or after the patient has gone to bed and has experienced difficulty falling asleep.”
Zaleplon 10 mg is usually taken by mouth as a single dose.
Label context consistent with oral dosing immediately before bedtime/after difficulty falling asleep; label excerpt specifies timing but does not explicitly state “single dose” in provided text (partial support).
Zaleplon is generally taken right before bedtime or when the person is ready to sleep.
Label excerpt: “immediately before bedtime or after… difficulty falling asleep.”
Common side effects of zaleplon include sleepiness.
Partially supported by label mention of CNS-depressant effects; provided excerpts do not list “sleepiness” as a specific common adverse event.
Common side effects of zaleplon include dizziness.
Provided excerpts do not list dizziness as an adverse reaction.
Common side effects of zaleplon include headaches.
Provided excerpts do not list headaches as an adverse reaction.
Unsupported Statements
Zaleplon may be used for short-term sleep problems.
Label excerpt supports “short-term treatment of insomnia,” but the response is phrased as general “short-term sleep problems” rather than insomnia and does not cite the label’s insomnia-specific wording.
Zaleplon is 10 mg is usually taken by mouth as a single dose.
Provided label excerpts specify recommended dose and timing, but the provided text does not explicitly state “single dose.”
Combining zaleplon with alcohol increases the risk of excessive sedation.
Provided label excerpts do not include alcohol interaction warnings/risks.
Combining zaleplon with alcohol increases the risk of impaired breathing.
Provided label excerpts do not include alcohol interaction warnings/risks.
Combining zaleplon with alcohol increases the risk of accidents.
Provided label excerpts do not include alcohol interaction warnings/risks.
Combining zaleplon with opioid pain medicines increases the risk of excessive sedation.
Provided label excerpts do not include opioid interaction warnings/risks.
Combining zaleplon with opioid pain medicines increases the risk of impaired breathing.
Provided label excerpts do not include opioid interaction warnings/risks.
Combining zaleplon with opioid pain medicines increases the risk of accidents.
Provided label excerpts do not include opioid interaction warnings/risks.
Combining zaleplon with other sedatives or sleep drugs increases the risk of excessive sedation.
Provided label excerpts do not include specific “combining with sedatives/sleep drugs” interaction risk statements.
Combining zaleplon with other sedatives or sleep drugs increases the risk of impaired breathing.
Provided label excerpts do not include specific “combining with sedatives/sleep drugs” interaction risk statements.
Combining zaleplon with other sedatives or sleep drugs increases the risk of accidents.
Provided label excerpts do not include specific “combining with sedatives/sleep drugs” interaction risk statements.
Zaleplon is designed to work mainly around the time the dose is taken to help a person fall asleep.
The label excerpts emphasize rapid onset and timing, but the statement adds “mainly around the time the dose is taken” as a mechanistic emphasis not explicitly present in the provided text.
Taking zaleplon and then staying awake increases the chance of impaired function.
Provided excerpts do not state “increases the chance of impaired function” for staying awake.
Seek medical help urgently for severe allergic reactions with swelling of face or throat and trouble breathing.
Provided label excerpts include hypersensitivity contraindication but do not provide this specific urgent symptom guidance.
Seek medical help urgently for extreme confusion.
Provided label excerpts do not mention “extreme confusion” as a specifically described urgent adverse event.
Seek medical help urgently for fainting.
Provided label excerpts do not mention fainting as an urgent symptom.
Seek medical help urgently for trouble breathing.
Provided label excerpts mention caution regarding respiratory effects but do not provide this specific urgent action statement.
Contact a clinician if unusual behaviors occur with zaleplon.
Provided label excerpts do not contain this specific instruction.
Contact a clinician if depression worsens or suicidal thoughts occur with zaleplon.
Provided label excerpts do not contain this specific instruction.
Contradictions
Low
AI Statement
Zaleplon may be used for short-term sleep problems.
Label Reference
Label indicates “short-term treatment of insomnia,” not general “sleep problems.”
Low
AI Statement
Zaleplon is usually taken by mouth as a single dose.
Label Reference
Dose is described as recommended dose and timing; the provided label excerpts do not explicitly confirm “single dose.”
Important Omissions
Individualization and specific dosing limits: recommended 10 mg for most nonelderly adults; 5 mg for certain low weight individuals; 20 mg may be considered for occasional patients not benefiting from lower dose; doses above 20 mg are not recommended.
Importance:
Moderate
Elderly-specific guidance: dose of 5 mg recommended for elderly patients to decrease possibility of side effects.
Importance:
Moderate
Contraindication wording: hypersensitivity to zaleplon or excipients.
Importance:
Moderate
Label efficacy nuance: insomnia should be evaluated if not remitting after 7–10 days; label also states efficacy focus is time to sleep onset and not demonstrated to increase total sleep time or decrease awakenings.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple interaction and urgent-symptom claims are not supported by the provided label excerpts, and key dosing limit/individualization information is omitted, which could affect accurate prescribing context.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Review
Primary Issue
Several safety and interaction assertions (alcohol/opioids/sedatives; specific urgent adverse-event guidance) are not supported by the supplied labeling excerpts, and key dosing/contraindication details are omitted.
Suggested Improvement
Limit claims to the provided label sections: short-term insomnia indication and reduction in sleep onset latency; timing immediately before bedtime/after difficulty falling asleep; include dosing individualized to nonelderly/low weight/elderly and the 20 mg maximum; add hypersensitivity contraindication; remove or qualify interaction and urgent symptom guidance unless supported by the provided label text.